Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Mars 2012
Génomique et recherche clinique en oncologie : approches de sciences humaines, économiques et sociales (SHES)
Page(s) 14 - 18
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2012281s105
Publié en ligne 9 avril 2012
  1. Bertucci F, Houlgatte R, Nguyen C, et al. Gene expression profiling of cancer by use of DNA arrays: how far from the clinic? Lancet Oncol 2001 ; 2 : 674–682. [CrossRef] [PubMed]
  2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000 ; 406 : 747–752. [CrossRef] [PubMed]
  3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001 ; 98 : 10869–10874. [CrossRef]
  4. Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004 ; 10 : 5508–5517. [CrossRef] [PubMed]
  5. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005 ; 65 : 9155–9158. [CrossRef] [PubMed]
  6. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005 ; 65 : 2170–2178. [CrossRef] [PubMed]
  7. Prat A, Parker JS, Karginova O, et al. Phenotypic, molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010 ; 12 : R68. [CrossRef] [PubMed]
  8. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009 ; 360 : 790–800. [CrossRef] [PubMed]
  9. Bertucci F, Finetti P, Cervera N, Birnbaum D. Classification pronostique du cancer du sein et profils d’expression génique sur puces à ADN. Med Sci (Paris) 2008 ; 24 : 599–606. [CrossRef] [EDP Sciences] [PubMed]
  10. van ’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 ; 415 : 530–536. [CrossRef] [PubMed]
  11. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999–2009. [CrossRef] [PubMed]
  12. Buyse M, Loi S, van’t Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006 ; 98 : 1183–1192. [CrossRef] [PubMed]
  13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817–2826. [CrossRef] [PubMed]
  14. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004 ; 5 : 607–616. [CrossRef] [PubMed]
  15. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006 ; 98 : 262–272. [CrossRef] [PubMed]
  16. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006 ; 24 : 4236–4244. [CrossRef] [PubMed]
  17. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011 ; 29 : 1578–1586. [CrossRef] [PubMed]
  18. Bertucci F, Borie N, Roche H, et al. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2011 ; 127 : 363–373. [CrossRef] [PubMed]
  19. Gravier E, Pierron G, Vincent-Salomon A, et al. A prognostic DNA signature for T1T2 node-negative breast cancer patients. Genes Chromosomes Cancer 2010 ; 49 : 1125–1134. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  20. Zhang Y, Martens JW, Yu JX, et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res 2009 ; 69 : 3795–3801. [CrossRef] [PubMed]
  21. Sircoulomb F, Nicolas N, Ferrari A, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 2011 ; 3 : 153–166. [CrossRef] [PubMed]
  22. Mills RE, Walter K, Stewart C, et al. Mapping copy number variation by population-scale genome sequencing. Nature 2011 ; 470 : 59–65. [CrossRef] [PubMed]
  23. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009 ; 41 : 579–584. [CrossRef] [PubMed]
  24. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010 ; 28 : 4674–4682. [CrossRef] [PubMed]
  25. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 ; 66 : 3992–3995. [CrossRef] [PubMed]
  26. Cardoso F, Van’t Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008 ; 26 : 729–735. [CrossRef] [PubMed]
  27. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008 ; 26 : 721–728. [CrossRef] [PubMed]
  28. Tabchy A, Valero V, Vidaurre T, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010 ; 16 : 5351–5361. [CrossRef] [PubMed]
  29. Bertucci F, Ferrero JM, Bachelot T, et al. SA02 trial: a genomics-based prospective study of adjuvant chemotherapy in node-positive early breast cancer with good-prognosis signature. San Antonio, TX: Breast Cancer Symposium, 2009.
  30. Bild AH, Parker JS, Gustafson AM, et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res 2009 ; 11 : R55. [CrossRef] [PubMed]
  31. Von Hoff DD, Stephenson JJ, Jr, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010 ; 28 : 4877–4883. [CrossRef] [PubMed]
  32. Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 2011 ; 29 : 1236–1238. [CrossRef] [PubMed]
  33. Tursz T, Andre F, Lazar V, LaCroix L, Soria JC. Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol 2011 ; 8 : 177–183. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.